Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01880788 · ClinicalTrials.gov registry record

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

A clinical trial of Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Sequenom.

Completed
Registry status
152
Enrollment target
1
Study location

NCT01880788 is a study of Age-related Macular Degeneration and Choroidal Neovascularization that has completed, run by Sequenom. The registered enrollment target is 152 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01880788, a study of Age-related Macular Degeneration and Choroidal Neovascularization, has completed, sponsored by Sequenom.

COMPLETED
Registry status
152 participants
Enrollment target
1
Study location

Study Summary

The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis. Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

Study Locations (1)

New York

  • Vitreous Retina Macula Consultants of New York - New York

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2012-11
Est. Completion 2015-08

Sponsor

Sequenom

26 total trials

What the Registry Record Tells You About NCT01880788

The ClinicalTrials.gov registry entry for NCT01880788 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (90% lower). The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.

NCT01880788 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01880788 about?

NCT01880788 is a clinical study titled "Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD". The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis. Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

What is the current status of trial NCT01880788?

This trial is currently completed. The enrollment target is 152 participants. The study started on 2012-11. Estimated completion is 2015-08.

What conditions does trial NCT01880788 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy.

Who is sponsoring clinical trial NCT01880788?

This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01880788 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.